Aquilo Capital

Aquilo Capital Management, LLC operates as a healthcare-focused long/short hedge fund, primarily investing in drug development companies. The firm applies its expertise to identify and capitalize on opportunities within the biotechnology sector, supporting entities that leverage advanced scientific research. Its investment approach centers on backing innovative companies dedicated to developing solutions for significant medical needs.

The firm was founded in 2010 by Marc Schneidman, who serves as Founder and Chief Investment Officer. Schneidman established Aquilo Capital Management based on his extensive background, bringing over two decades of dedicated investment experience across the biotechnology universe. This deep domain knowledge informed the firm's specialized focus on the intricacies of drug development.

Aquilo Capital Management’s strategy targets promising drug development enterprises, acting as an investment partner to help advance their pipelines. Its overarching vision is to contribute to medical progress by channeling capital toward scientific breakthroughs, ultimately aiming to address urgent medical requirements and generate returns for its investors through strategic participation in the life sciences landscape.